key: cord-0787463-hmjzv3qp
authors: Guddeti, Raviteja R.; Yildiz, Mehmet; Nayak, Keshav R.; Alraies, M. Chadi; Davidson, Laura; Henry, Timothy D.; Garcia, Santiago
title: Impact of COVID-19 on Acute Myocardial Infarction Care
date: 2022-03-23
journal: Cardiol Clin
DOI: 10.1016/j.ccl.2022.03.004
sha: 9a90611039718893c9f33d2507c29e21667bd8fa
doc_id: 787463
cord_uid: hmjzv3qp

The global health crisis caused by the coronavirus disease-2019 (COVID-19) pandemic has evolved rapidly to overburden healthcare organizations around the world and has resulted in significant morbidity and mortality. Many countries have reported a substantial and rapid reduction in hospital admissions for acute coronary syndromes (ACS) and percutaneous coronary intervention. The reasons for such abrupt changes in healthcare delivery are multifactorial and include lockdowns, reduction in outpatient services, reluctance to seek medical attention for fear of contracting the virus, and restrictive visitation policies adopted during the pandemic. Diversion of hospital resources towards treating COVID-19 patients not only overwhelmed emergency medical services, the additional lack of appropriate resources to transfer patients to PCI-capable hospitals further added to reduced hospital admissions for acute MI. Lastly, healthcare systems across the globe have reported worse MI performance metrics during the pandemic. In this review, we provide an overview of the impact of COVID-19 on important aspects of acute MI care.

This outbreak has quickly overwhelmed healthcare systems around the world consuming and shifting resources to care for these patients, resulting in deferral or avoidance of care for many non-covid patients, placing those with other health conditions at risk due to limited access to high-quality medical care. Similarly, patients with cardiovascular diseases have been greatly affected as a result. At the beginning of the pandemic, many elective cardiac procedures were cancelled to minimize exposure to cardiac catheterization laboratory personnel and nursing staff with priority given only to management of ST-elevation myocardial infarction (STEMI) and critically ill non-ST elevation myocardial infarction (NSTEMI) patients.

Despite a declining trend in overall incidence, acute MI continues to remain a condition with high morbidity and mortality, with an incidence of 805,000 cases annually. 1 Timely coronary J o u r n a l P r e -p r o o f revascularization, achieved by primary percutaneous coronary intervention (PPCI), remains the mainstay of management for acute MI. Data from around the world during the pandemic suggested significantly lower rates of hospitalizations for acute MI, both STEMI, and NSTEMI, either due to lower referral rates, patients' hesitancy to seek health care in fear of contracting COVID-19 at the hospitals or even misdiagnosis. [2] [3] [4] [5] [6] [7] [8] We discuss the impact of COVID-19 on the treatment important aspects of acute MI.

The COVID-19 pandemic has had a dramatic negative impact on the overall care of STEMI patients (Figure 1 ). [2] [3] [4] [5] [6] [7] [8] The areas most impacted by COVID-19 include:

• Reduction in STEMI activations

• Prolonged symptom-to-first medical contact time

• Prolonged door-to-balloon times • A shift from PPCI to pharmacological reperfusion (i.e., fibrinolytic therapy)

• Reduction in patients undergoing invasive angiography and PPCI

• Worsening clinical outcomes

Compared to the pre-pandemic years, STEMI activations were reduced significantly during the early months of the pandemic. This decrease in STEMI admissions was seen irrespective of age, gender, underlying co-morbidities, and geographic region. In the first 3 J o u r n a l P r e -p r o o f months of the pandemic between January 2020 to March 2020, a 38% reduction in STEMI activations was noted in the United States compared to the same time period the previous year. 2 An expanded and extended analysis of the US that included 18 large healthcare systems showed a drop in STEMI activations of about 29%. 9 Interestingly, this drop in STEMI activations affected all geographic regions irrespective of COVID-19 incidence or stay at home orders. 9 A similar trend has been reported around the world (Figure 2) . 5, 8, 10 This decrease in STEMI activations coincided with a significant increase in out of hospital cardiac arrests, which raised concerns about patients with cardiovascular emergencies foregoing medical care during the pandemic. 11 An increase in mechanical complications of STEMI was also noted. 12 Using data from a National Patient Care database from January 2019 to May 2020, a 23% reduction in weekly STEMI admission rates was reported in the United Kingdom between mid-February and the end of March 2020 compared with the weekly average admissions in 2019. 6 This decline was partially reversed in April and May 2020 to a weekly reduction of 16% by the end of the study period. Similarly, data from Italy showed in March 2020 there was a 26.5% reduction in STEMI admissions compared to the same time period the year before. 5 Interestingly, the reduction in admissions was higher among women compared to men (41.2% vs 17.8%) which could represent gender disparity in the management of STEMI during the pandemic.

In addition to the reluctance to seek medical attention by patients out of fear of contracting COVID-19, other potential explanations for the lower rate of STEMI activations during the pandemic include a shift to pharmacological reperfusion to minimize operator exposure, misdiagnosis of STEMI, and changes in standard of care, including personal protective equipment (PPE), emergency medical services, rapid testing and hospital beds, and a shift in resources to J o u r n a l P r e -p r o o f care for COVID-19 patients. It is unlikely that the reduction in STEMI represents reduced MI incidence related to less physical and work-related stress. The increased numbers of cardiac arrest and late complications of STEMI would suggest otherwise.

While evidence suggests that reduced door-to-balloon times have significantly improved outcomes in STEMI 13, 14 , patient-related delay (symptom to first medical contact) remains a significant challenge. The total ischemic time, defined as symptom onset to revascularization, is a major determinant of outcomes in STEMI. 15, 16, 17 During the current pandemic, this important metric was significantly longer compared to that in the pre-COVID era as demonstrated by Abdelaziz et al. 10 In this study, once the patient presented to the hospital, the door-to-balloon time was similar between the two groups, but troponin levels were significantly higher in the 52%, p <0.01) and a higher rate of intramyocardial hemorrhage (56% versus 34%, p = 0.02). 19 Both patient-and system-related factors appear to have contributed to delay in symptom-to first medical contact and door-to-balloon times during the pandemic, which limits the substantial benefit provided by primary PCI in STEMI. Fear of contracting COVID-19 infection at the hospital or the physician's office often seems to have led patients to delay seeking appropriate care for chest pain. Early in the pandemic, healthcare systems were stressed which impacted timely management of STEMI patients. Multiple countries implemented strict lockdowns to prevent the spread of COVID-19 with both hospital and emergency medical services redirected to critically ill COVID-19 patients. Longer EMS response times and shortages of experienced EMS personnel contributed to delays in cardiac catheterization laboratory activations from the field. These differences were more pronounced in countries that entered the pandemic with limited health care resources in infrastructure and personnel. In a systematic review, Chew et al demonstrated that low-income countries reported a larger increase in doorto-balloon times compared to high-income countries (19.64 minutes vs 4.52 minutes). 20

Over the past two decades, there has been a decline in the use of fibrinolytic therapy for STEMI as extensive data demonstrated superior outcomes with PPCI compared to lytic therapy. 21 In the contemporary era, fibrinolytic therapy for STEMI is primarily used only for patients who initially present to a non-PCI-capable hospital with a transfer time to a PCI-capable center of >2 hours. At the beginning of the pandemic, a shift to fibrinolytic therapy was more strongly considered for the management of STEMI even in PPCI capable hospitals as healthcare organizations were severely overwhelmed with lack of appropriate resources, anticipated delays in primary PCI, and potential exposure of healthcare workers. 8, [22] [23] [24] In a small case series by Wang et al, 17 STEMI patients who received fibrinolytics were compared to 20 who underwent primary PCI. 24 This study showed comparable in-hospital and 30-day MACE, and mortality rates with no increase in major bleeding risk. By following a modified STEMI care protocol, where-in fibrinolysis was the preferred treatment of choice for patients with However, this approach has been associated with higher mortality, re-infarction, stroke, and major bleeding. 25, 26 Moreover, the benefit of fibrinolytic therapy was negated if there was a considerable delay in presentation, which could result in the formation of a more organized clot that may be resistant to lysis. While large-scale randomized studies comparing the two strategies J o u r n a l P r e -p r o o f in the pandemic era are lacking, the rationale for changing the standard of care from PPCI to fibrinolytic therapy has not been clearly established. Additionally, the Chinese experience has demonstrated more adverse events with this approach, including death and heart failure, and therefore this shift from mechanical to pharmacological reperfusion cannot be recommended.

Consistent with existing guidelines, a pharmaco-invasive approach can be considered for patients presenting initially to non-PCI-capable hospital when timely transfer to a PCI-capable hospital is not available. 14

Primary PCI, when available and performed by an experienced team in a timely manner, is the preferred reperfusion strategy for treating STEMI improve survival and reduce rates of recurrent MI and hemorrhagic stroke relative to lytic therapy. 13, 21, 25 During the pandemic there have been significant reductions in primary PCI rates for STEMI, which paralleled reductions in hospital admissions for STEMI. In The United Kingdom, an 18% reduction in weekly primary PCI rates for STEMI was observed during the first few months of the pandemic compared to the previous year. 18 Similarly, data from the European ISACS-STEMI COVID-19 registry showed a 19% reduction in primary PCI rates between March and April 2020 compared to the same time period the previous year. 18 to PPCI during the pandemic may be a desire to avoid the healthcare system during the pandemic, in particular during lockdowns. 5

Delayed reperfusion in STEMI is associated with larger myocardial scar size, increased risk of heart failure and shock, ventricular arrhythmias, and mortality. 27 There has been an increased risk of mortality and worse outcomes in STEMI patients during the pandemic. STEMI case fatality rate in Italy was 13.7% during the pandemic compared to 4.1% the previous year, a 3-fold increase in mortality. 5 In addition, there was a higher prevalence of major complications (cardiogenic shock, life-threatening arrhythmias, cardiac rupture/ventricular septal defect, and severe functional mitral regurgitation) in these patients during the study period, an increase from 10.4% to 18.8%. In addition, Chew et al demonstrated that there was a higher proportion of patients with post-PCI fibrinolysis in myocardial infarction (TIMI) flow grade <3 during the pandemic compared to the pre-pandemic era indicating suboptimal reperfusion. 20 In the European ISACS-STEMI COVID-19 registry, the overall in-hospital mortality rate in STEMI patients was significantly higher at 6.8% during the pandemic compared to 4.9% the prior year. 18 This association between COVID-19 pandemic and higher in-hospital mortality rates persisted even after adjusting for longer total ischemic and door-to-balloon times. There were more late STEMI presentations during the pandemic. While the true incidence of post-STEMI mechanical complications during the pandemic is currently unknown 12 , Araiza-Garaygordobil et al demonstrated an incidence of 1.98% compared to 0.98% in the pre-pandemic era in one multinational study, despite similar GRACE risk scores. 28 The increase in short-term complications J o u r n a l P r e -p r o o f may lead to prolonged admission to critical care units which could, in turn, exacerbate a serious shortage in already sparse resources.

Potential causes for worse outcomes in STEMI include prolonged symptom-to-coronary angiography time due to need to test patients for COVID prior to transport to the CV lab, late presentations, reduced rates of primary PCI, and a switch from mechanical to pharmacological reperfusion. Patients presenting initially to non-PCI hospitals may experience transfer delays or even refusal to transfer due to COVID-19 related healthcare demands and resource limitations.

At the beginning of the pandemic, cardiac catheterization laboratories in some hospitals were suspended to limit exposure until specific hospital-wide protocols were initiated to maintain the safety of personnel and minimize exposure. 14 Also, STEMI protocols were altered during the pandemic to allow for screening and triaging of COVID-19 patients in the emergency department, which could have led to further delays in reperfusion and worse outcomes. 14

Similar to STEMI, a significant reduction in hospital admissions for NSTEMI has been reported during the pandemic. [3] [4] [5] In fact, reductions in hospital admissions and PCI rates for NSTEMI were more pronounced than that seen for STEMI. 6 Compared to a 23% reduction in weekly STEMI admissions, Mafham et al reported a 42% reduction in NSTEMI admissions. 6 Data from Italy showed a 65.4% reduction in hospital admissions for NSTEMI. 5 This was significantly higher compared to a 26.5% reduction in STEMI admissions during the same study period.

J o u r n a l P r e -p r o o f at the beginning of the pandemic in the United States. 4 One possible explanation for this observation is that STEMI patients who present with more severe symptoms tend to seek help more often than patients with NSTEMI.

In a small single-center study Aldujeli 29 Although symptom-to-revascularization time is less frequently studied in patients with NSTEMI/UA, studies have demonstrated worse outcomes in high-risk patients when revascularization is delayed. 30 A change in revascularization modalities has also occurred during the pandemic. Mafham et al observed that NSTEMI patients were more likely to undergo PCI rather than coronary artery bypass graft surgery (CABG) surgery (up to 80% reduction in CABG surgery), which was in line with the recommendations from the British Cardiovascular Intervention Society to minimize utilization of intensive care unit beds. 6 Moreover, there was also a paucity of mechanical ventilators due to the diversion of resources to critically ill COVID-19 patients. Interestingly, these patients received PCI more often on the day of admission resulting in a shorter length of hospital stays, to minimize exposure and make beds available for sicker COVID-19 patients. Despite this shift away from CABG surgery, there was a 37% reduction in weekly PCI rates for NSTEMI during the pandemic compared to the year prior.

In addition to reduced hospitalizations and prolonged symptom-to-revascularization times, the rate of major complications (cardiogenic shock, life-threatening arrhythmias, cardiac J o u r n a l P r e -p r o o f rupture/ventricular septal defect, and severe functional mitral regurgitation) was reported to have increased from 5.1% to 10.7% in NSTEMI in one study. 5

Myocardial injury, defined as an elevation in troponin levels above the 99 th percentile, is common in hospitalized patients with COVID-19 infection with a incidence ranging between 8% and 36% (See Chapter 2). 31, 32 The incidence of myocardial injury parallels the severity of COVID-19 infection with a 13-fold increase in risk among patients in intensive care units. 31 Troponin elevation in COVID-19 is independently associated with increased risk of mortality, especially those with underlying history of cardiovascular disease. 33, 34 Differential diagnoses for elevated troponin in COVID-19 include acute MI, microvascular thrombosis, acute heart failure, myocarditis, stress-induced cardiomyopathy, supply-demand mismatch, disseminated intravascular coagulation, cytokine storm, and lastly acute pulmonary embolism. 35 COVID-19 may increase the risk of acute MI with a reported incidence between 1.1% and 8.9%. 36, 37 The risk is higher in the first 2 weeks following infection with Modin et al showing an approximately 5-fold increased risk. 38 A large population-based study of all COVID-19 patients in Sweden reported that the risk of acute MI in these patients is significantly higher in the first one week after exposure and subsequently decreases by weeks 2 and 3. 39 The pathophysiology of acute MI in COVID-19 include 1) increased risk of plaque rupture and thrombosis (type 1 AMI) or 2) myocardial oxygen imbalance due to supply-demand mismatch (type 2 AMI). This is attributed The diagnosis of acute MI become more challenging for clinicians around the world during these unprecedented times. In COVID-19 patients it is crucial to differentiate ACS and myocardial injury as treatment varies significantly. While the same criteria can be used to diagnose STEMI in COVID-19 patients compared to the general population, the diagnosis of NSTEMI can be particularly challenging as troponin elevation is commonly seen in these patients. COVID-19

patients presenting with acute MI may have complex coronary anatomy with higher thrombus burden, lesion haziness, ulcerative lesions, and prevalence of multivessel CAD. 41 The prothrombotic state associated with COVID-19 infection could possibly play a role in a higher thrombus burden in acute MI patients.

Early in the pandemic, De Rosa et al reported that among all STEMI patients, 10.7% were COVID+ with a case fatality rate of 28.6% compared to 11% in COVID-patients. 5 Similarly, inhospital mortality from STEMI in COVID-19 patients was 29% from the European ISACS-STEMI COVID-19 registry. 18 The North American COVID-19 Myocardial Infarction (NACMI) registry, a prospective, multicenter, observational registry of hospitalized STEMI patients with confirmed COVID-19 infection comprehensively evaluated patient characteristics in this high-risk population. 42 This important registry has shown that one in five COVID-19 patients with STEMI did not undergo invasive coronary angiogram and among those who did about 1 in 4 had normal coronary arteries. In addition, the study demonstrated that despite having a high-risk presentation with more cardiogenic shock, COVID-19 patients were less likely to undergo PCI (71% vs 100%), had significantly longer door-to-balloon times (79 min vs 66 min), and significantly J o u r n a l P r e -p r o o f higher in-hospital mortality (33% vs 4%) compared to age-and sex-matched historical controls.

Despite this, primary PCI remained the preferred revascularization strategy in these patients with a 48% mortality among those who did not undergo coronary angiogram compared to 28% among those who did. This highlights the feasibility of primary PCI in COVID-19 patients, which remains the recommended modality of revascularization in STEMI. 13 The European Association for Cardiovascular Imaging (EACVI) and the American Association of Cardiology (ACC) have highlighted recommendations to help guide clinicians in making appropriate decisions with regards to caring for patients suspected or diagnosed to have COVID-related acute myocardial injury. 14, 43 Acute MI care in COVID-19 patients is discussed in detail in chapter 5.

It is clear that the COVID-19 pandemic continues to have a negative impact on acute myocardial infarction care. Conceptually, the COVID-19 pandemic has had direct (increased arterial and venous thrombogenicity, troponin elevation, microthrombi, respiratory failure, inhospital presentation) and indirect effects (lockdowns, cancellation of services, restrictive visitation policies, delayed presentations) on acute MI are, which collectively have resulted in increased morbidity and mortality. 44 A thorough understanding of the barriers to seeking and providing cardiovascular care in acute MI during this pandemic is crucial to improving outcomes. Primary PCI continues to be the preferred treatment of choice in STEMI patients and studies have demonstrated worse outcomes J o u r n a l P r e -p r o o f in those who did not receive primary PCI during the pandemic. 22 44 For effective results, such campaigns should be able to cross cultural, socioeconomic, and psychosocial barriers. Strategies for emergency network reorganization, including rapid screening of acute MI patients and appropriate allocation of resources for critically ill non-COVID patients, are also needed. System-wide standardized protocols need to be implemented by healthcare organizations to ensure rapid, and safe access to healthcare in a timely manner for improved outcomes in acute MI while ensuring the safety of the healthcare personnel.

Interruptions in critical healthcare services have been reported during prior epidemics/pandemics. The American Heart Association issued temporary emergency guidance on STEMI care that included improving awareness among the general public about the symptoms and signs of "heart attack", screening patients for COVID symptoms, identifying STEMI mimics prior to catheterization lab activation, and minimizing delays to primary PCI for clear STEMI while testing for COVID-19. 46 PCI was recommended as the preferred primary reperfusion strategy in these patients irrespective of their COVID status. The Society for Cardiovascular Angiography and J o u r n a l P r e -p r o o f Interventions (SCAI), the American College of Cardiology (ACC) and the American College of Emergency Physicians (ACEP) advocate that those patients needing emergency cardiac catheterization should be treated as possible COVID-19 and treated accordingly pending testing. 14 Cardiovascular societies and healthcare organizations need to continue to work together to formulate pragmatic guidelines and protocols with the goal of delivering the best possible care for acute MI patients while maintaining the safety of hospital personnel in these troubled times.

The COVID-19 pandemic has resulted in restricted access to clinical services and worse clinical outcomes for patients with acute MI. The mechanisms are multifactorial and include avoidance of medical care during lockdowns, late presentations, reorganization of treatment pathwaysincluding deviations from standard of care protocols during COVID surges-, and a shift from mechanical to pharmacological reperfusion. Many of these trends have the potential to undo 3

Heart Disease and Stroke Statistics-2019 Update: A Report From the

Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic

Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy

The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction

Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era

COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England

Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic

Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center

Characteristics Associated With Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease

Back to the Future" for STEMI?: The COVID-19 Experience. JACC Case Rep

Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for

the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)

Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty

Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts

System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention

Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI

Impact of COVID-19 pandemic restrictions on STelevation myocardial infarction: a cardiac magnetic resonance imaging study

The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak

Experiences and lesson strategies for cardiology from the COVID-19 outbreak in Wuhan, China, by 'on the scene' cardiologists

Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic

Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction

Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: bayesian hierarchical meta-analyses of randomized controlled trials and observational studies

Left ventricular remodeling and ventricular arrhythmias after myocardial infarction

Impact of the COVID-19 pandemic on hospitalizations for acute coronary syndromes: a multinational study

Delays in Presentation in Patients With Acute Myocardial Infarction During the COVID-19 Pandemic

Admissions Rate and Timing of Revascularization in the United States in Patients With Non-ST-Elevation Myocardial Infarction

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

COVID-19 and the cardiovascular system

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Acute COVID-19 and the Incidence of 41

Patients with COVID-19 who experience a myocardial infarction have complex coronary morphology and high in-hospital mortality: Primary results of a nationwide angiographic study

Initial Findings From the North American

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel

The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world

American Heart Association's Mission L, Get With The Guidelines Coronary Artery Disease Advisory Work G, the Council on Clinical Cardiology's Committees on Acute Cardiac C, General C, Interventional Cardiovascular C. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA's Mission: Lifeline